Overview

Treatment of Pain Associated With Fibromyalgia

Status:
Completed

Trial end date:
2016-07-14

Target enrollment:

Participant gender:

Summary

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Collaborators:

INC Research
Syneos Health

Treatments:

Pregabalin